At the American Society of Clinical Oncology meeting, data from a small retrospective analysis suggest that diabetic patients with breast cancer had significantly higher rates of response to neoadjuvant chemotherapy if they took metformin.
References and Resources
Jiralerspong S, et al. The effects of metformin on pathologic complete response (pCR) rates in diabetic breast cancer (BC) patients receiving neoadjuvant systemic therapy (NST). ASCO Meeting 2008; Abstract 528.
Sponsored by The Doctor’s Channel